Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.35 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532270 | 1.00 | CYP11B1 (0.46) | CYP11B1CYP11B2CMA1EPAS1VEGFA | |
| SCHEMBL15533210 | 0.81 | CYP11B1 (0.42) | CYP11B1CYP11B2EPAS1UGT2B17S1PR1 | |
| SCHEMBL15532010 | 0.81 | CYP11B1 (0.42) | CYP11B1CYP11B2UGT2B17S1PR1 | |
| SCHEMBL9279331 | 0.81 | UGT2B17 (0.51) | CYP11B1CYP11B2UGT2B17S1PR1 | |
| SCHEMBL16790852 | 0.79 | CMA1 (0.37) | CYP11B1CYP11B2CMA1 | |
| SCHEMBL29895192 | 0.78 | IDO1 (0.39) | CYP11B1CYP11B2EPAS1VEGFAUGT2B17 | |
| SCHEMBL22143614 | 0.78 | IDO1 (0.39) | CYP11B1CYP11B2EPAS1VEGFAUGT2B17 | |
| SCHEMBL8612191 | 0.78 | IDO1 (0.39) | CYP11B1CYP11B2EPAS1VEGFAUGT2B17 | |
| SCHEMBL1688155 | 0.76 | CMA1 (0.35) | CYP11B1CYP11B2CMA1 | |
| SCHEMBL24387388 | 0.75 | EPAS1 (0.37) | CYP11B1CYP11B2EPAS1VEGFAUGT2B17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646425-B1 | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2289868-B1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| CN-102076650-A | Carboxylic acid compound | DAIICHI SANKYO CO LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | CYP11B1 79/4885CYP11B2 106/4885CMA1 564/4885 |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | CYP11B1 383/4885CYP11B2 482/4885CMA1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.